Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother-infant pairs

Journal of Antimicrobial Chemotherapy

Volumn 73, Issue 4, 2018, Pages 1013-1019

  Waitt, Catriona ^a,b,c   Olagunju, Adeniyi ^a,d   Nakalema, Shadia ^b   Kyohaire, Isabella ^b   Owen, Andrew ^a   Lamorde, Mohammed ^b   Khoo, Saye ^a,c  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^c ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^d OBAFEMI AWOLOWO UNIVERSITY   (Nigeria)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE; LAMIVUDINE; TENOFOVIR DISOPROXIL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; TENOFOVIR;

AFRICAN; AREA UNDER THE CURVE; ARTICLE; BREAST FEEDING; BREAST MILK; CLINICAL ARTICLE; CONTROLLED STUDY; DRIED BLOOD SPOT TESTING; DRUG BLOOD LEVEL; FEMALE; HUMAN; INFANT; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MATERNAL BLOOD; MATERNAL PLASMA; MAXIMUM CONCENTRATION; MOTHER CHILD RELATION; NIGERIAN; PHARMACOKINETIC PARAMETERS; TIME TO MAXIMUM PLASMA CONCENTRATION; UGANDAN; ADULT; CHEMISTRY; COHORT ANALYSIS; LIQUID CHROMATOGRAPHY; MALE; MOTHER; NIGERIA; PLASMA; TANDEM MASS SPECTROMETRY; UGANDA; YOUNG ADULT;

ADULT; ANTI-HIV AGENTS; BREAST FEEDING; CHROMATOGRAPHY, LIQUID; COHORT STUDIES; EMTRICITABINE; FEMALE; HUMANS; INFANT; LAMIVUDINE; MALE; MILK, HUMAN; MOTHERS; NIGERIA; PLASMA; TANDEM MASS SPECTROMETRY; TENOFOVIR; UGANDA; YOUNG ADULT;

EID: 85044858049     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkx507     Document Type: Article

References (18)

1. United Nations Children's Fund (UNICEF). For Every Child, End AIDS. Seventh Stocktaking Report, 2016. New York, NY, USA: UNICEF, 2016. https:// data.unicef.org/wp-content/uploads/2016/12/HIV-and-AIDS-2016-Seventh-Stocktaking-Report.pdf.
2. WHO. Guideline. Updates on HIV and Infant Feeding. The Duration of breastfeeding and Support FromHealth Services to Improve Feeding Practices Among Mothers Living With HIV. Geneva, Switzerland: WHO, 2016. http://www.who. int/maternal_child_adolescent/documents/hiv-infant-feeding-2016/en/.
3. WHO. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Recommendations for a Public Health Approach-Second Edition. Geneva, Switzerland: WHO, 2016. http://www. who.int/hiv/pub/arv/arv-2016/en/.
4. Fogel JM, Mwatha A, Richardson P, et al. Impact of maternal and infant antiretroviral drug regimens on drug resistance in HIV-infected breastfeeding infants. Pediatr Infect Dis J 2013; 32: e164-9.
5. Zeh C, Weidle PJ, Nafisa L, et al. HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis. PLoS Med 2011; 8: e1000430.
6. Nachega JB, Uthman OA, Mofenson LM, et al. Safety of tenofovir disoproxil fumarate-based antiretroviral therapy regimens in pregnancy for HIVinfected women and their infants: a systematic review and meta-analysis. J Acquir Immune Defic Syndr 2017; 76: 1-12.
7. Olagunju A, Bolaji O, Amara A, et al. Breastmilk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother-infant pairs: an observational study. Clin Infect Dis 2015; 61: 453-63.
8. Corbett AH, Kayira D, White NR, et al. Antiretroviral pharmacokinetics in mothers and breastfeeding infants from 6 to 24 weeks post partum: results of the BAN Study. Antivir Ther 2014; 19: 587-95.
9. Benaboud S, Pruvost A, Coffie PA, et al. Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Cote d'Ivoire, in the ANRS 12109 TEmAA Study, Step 2. Antimicrob Agents Chemother 2011; 55: 1315-7.
10. Mirochnick M, Taha T, Kreitchmann R, et al. Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life. J Acquir ImmuneDefic Syndr 2014; 65: 33-41.
11. Palombi L, Pirillo MF, Marchei E, et al. Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach inMalawi.JAntimicrobChemother 2016; 71: 1027-30.
12. Olagunju A, Amara A, Waitt C, et al. Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots.JAntimicrobChemother 2015; 70: 2816-22.
13. Olagunju A, Khoo S, Owen A. Pharmacogenetics of nevirapine excretion into breast milk and infants' exposure through breast milk versus postexposure prophylaxis. Pharmacogenomics 2016; 17: 891-906.
14. Olagunju A, Bolaji OO, Amara A, et al. Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS. J Antimicrob Chemother 2015; 70: 555-61.
15. Waitt C, Dilly Penchala S, Olagunju A, et al. Development, validation and clinical application of a method for the simultaneous quantification of lamivudine, emtricitabine and tenofovir in dried blood and dried breast milk spots using LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2017; 1060: 300-7.
16. Zheng JH, Guida LA, Rower C, et al. Quantitation of tenofovir and emtricitabine in dried blood spots (DBS) with LC-MS/MS. J Pharm Biomed Anal 2014; 88: 144-51.
17. Waitt CJ, Garner P, Bonnett LJ, et al. Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and meta-analysis of pharmacokinetic studies. J Antimicrob Chemother 2015; 70: 1928-41.
18. Mugwanya KK, Hendrix CW, Mugo NR, et al. Pre-exposure prophylaxis use by breastfeeding HIV-uninfected women: a prospective short-term study of antiretroviral excretion in breast milk and infant absorption. PLoS Med 2016; 13: e1002132.